Literature DB >> 21640165

Impact of methamphetamine on dopamine neurons in primates is dependent on age: implications for development of Parkinson's disease.

B A Morrow1, R H Roth, D E Redmond, J D Elsworth.   

Abstract

Methamphetamine is a CNS stimulant with limited therapeutic indications, but is widely abused. Short-term exposure to higher doses, or long-term exposure to lower doses, of methamphetamine induces lasting damage to nigrostriatal dopamine neurons in man and animals. Strong evidence indicates that the mechanism for this detrimental effect on dopamine neurons involves oxidative stress exerted by reactive oxygen species. This study investigates the relative susceptibility of dopamine neurons in mid-gestation, young, and adult (not aged) monkeys to four treatments with methamphetamine over 2 days. Primate dopamine neurons undergo natural cell death at mid-gestation, and we hypothesized that during this event they are particularly vulnerable to oxidative stress. The results indicated that at mid-gestation and in adults, dopamine neurons were susceptible to methamphetamine-induced damage, as indicated by loss of striatal tyrosine hydroxylase (TH) immunoreactivity and dopamine concentration. However, dopamine neurons in young animals appeared totally resistant to the treatment, despite this group having higher brain levels of methamphetamine 3 h after administration than the adults. As a possible explanation for the protection, striatal glial-derived neurotrophic factor (GDNF) levels were elevated in young animals 1 week after treatment, but not in adults following methamphetamine treatment. Implications of these primate studies are: (1) the susceptibility of dopamine neurons at mid-gestation to methamphetamine warns against the risk of exposing pregnant women to the drug or oxidative stressors, and supports the hypothesis of Parkinson's disease being associated with oxidative stress during development, (2) elucidation of the mechanism of resistance of dopamine neurons in the young animals to methamphetamine-induced oxidative stress may provide targets for slowing or preventing age- or disease-related loss of adult nigrostriatal dopamine (DA) neurons, and (3) the increased striatal production of GDNF in young animals, but not in adults, in response to methamphetamine, suggests the possibility of an age-related change in the neurotrophic capacity of the striatal dopamine system.
Copyright © 2011 IBRO. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21640165      PMCID: PMC3150352          DOI: 10.1016/j.neuroscience.2011.05.046

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  73 in total

1.  Adult and in utero exposure to cocaine alters sensitivity to the Parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

Authors:  S A Lloyd; C J Faherty; R J Smeyne
Journal:  Neuroscience       Date:  2005-11-17       Impact factor: 3.590

2.  Amphetamine exposure is elevated in Parkinson's disease.

Authors:  Elisabeth R Garwood; Wosen Bekele; Charles E McCulloch; Chadwick W Christine
Journal:  Neurotoxicology       Date:  2006-03-28       Impact factor: 4.294

Review 3.  Mechanisms of methamphetamine-induced dopaminergic neurotoxicity.

Authors:  Evan L Riddle; Annette E Fleckenstein; Glen R Hanson
Journal:  AAPS J       Date:  2006       Impact factor: 4.009

Review 4.  GDNF family receptor complexes are emerging drug targets.

Authors:  Maxim M Bespalov; Mart Saarma
Journal:  Trends Pharmacol Sci       Date:  2007-01-10       Impact factor: 14.819

Review 5.  NTP-CERHR monograph on the potential human reproductive and developmental effects of amphetamines.

Authors: 
Journal:  NTP CERHR MON       Date:  2005-07

Review 6.  Oxidative stress in Parkinson's disease.

Authors:  Peter Jenner
Journal:  Ann Neurol       Date:  2003       Impact factor: 10.422

7.  Protection by GDNF and other trophic factors against the dopamine-depleting effects of neurotoxic doses of methamphetamine.

Authors:  Wayne A Cass; Laura E Peters; Michael E Harned; Kim B Seroogy
Journal:  Ann N Y Acad Sci       Date:  2006-08       Impact factor: 5.691

Review 8.  Progressive dopamine neuron loss in Parkinson's disease: the multiple hit hypothesis.

Authors:  Paul M Carvey; Ashok Punati; Mary B Newman
Journal:  Cell Transplant       Date:  2006       Impact factor: 4.064

9.  Restorative effects of GDNF on striatal dopamine release in rats treated with neurotoxic doses of methamphetamine.

Authors:  W A Cass; M W Manning; S L Bailey
Journal:  Ann N Y Acad Sci       Date:  2000-09       Impact factor: 5.691

Review 10.  Current research on methamphetamine-induced neurotoxicity: animal models of monoamine disruption.

Authors:  Taizo Kita; George C Wagner; Toshikatsu Nakashima
Journal:  J Pharmacol Sci       Date:  2003-07       Impact factor: 3.337

View more
  29 in total

Review 1.  Rodent models and contemporary molecular techniques: notable feats yet incomplete explanations of Parkinson's disease pathogenesis.

Authors:  Sharawan Yadav; Anubhuti Dixit; Sonal Agrawal; Ashish Singh; Garima Srivastava; Anand Kumar Singh; Pramod Kumar Srivastava; Om Prakash; Mahendra Pratap Singh
Journal:  Mol Neurobiol       Date:  2012-06-27       Impact factor: 5.590

Review 2.  Effects of prenatal methamphetamine exposure: a review of cognitive and neuroimaging studies.

Authors:  Maja A Kwiatkowski; Annerine Roos; Dan J Stein; Kevin G F Thomas; Kirsty Donald
Journal:  Metab Brain Dis       Date:  2013-12-28       Impact factor: 3.584

Review 3.  Monoamine reuptake inhibitors in Parkinson's disease.

Authors:  Philippe Huot; Susan H Fox; Jonathan M Brotchie
Journal:  Parkinsons Dis       Date:  2015-02-25

4.  Susceptibility to a parkinsonian toxin varies during primate development.

Authors:  B A Morrow; R H Roth; D E Redmond; S Diano; J D Elsworth
Journal:  Exp Neurol       Date:  2012-02-14       Impact factor: 5.330

5.  Role of GSK3β/α-synuclein axis in methamphetamine-induced neurotoxicity in PC12 cells.

Authors:  Lizeng Li; Si Chen; Yue Wang; Xia Yue; Jingtao Xu; Weibing Xie; Pingming Qiu; Chao Liu; AiFeng Wang; Huijun Wang
Journal:  Toxicol Res (Camb)       Date:  2017-12-22       Impact factor: 3.524

6.  Neurotrophic factors in women with crack cocaine dependence during early abstinence: the role of early life stress.

Authors:  Thiago W Viola; Saulo G Tractenberg; Mateus Luz Levandowski; Júlio Carlos Pezzi; Moisés Evandro Bauer; Antonio Lúcio Teixeira; Rodrigo Grassi-Oliveira
Journal:  J Psychiatry Neurosci       Date:  2014-05       Impact factor: 6.186

7.  Emerging neurotoxic mechanisms in environmental factors-induced neurodegeneration.

Authors:  Anumantha Kanthasamy; Huajun Jin; Vellareddy Anantharam; Gautam Sondarva; Velusamy Rangasamy; Ajay Rana; Arthi Kanthasamy
Journal:  Neurotoxicology       Date:  2012-02-07       Impact factor: 4.294

8.  Prenatal exposure to bisphenol A impacts midbrain dopamine neurons and hippocampal spine synapses in non-human primates.

Authors:  John D Elsworth; J David Jentsch; Catherine A Vandevoort; Robert H Roth; D Eugene Redmond; Csaba Leranth
Journal:  Neurotoxicology       Date:  2013-01-18       Impact factor: 4.294

9.  Developmental expression of paraoxonase 2.

Authors:  Jacqueline M Garrick; Khoi Dao; Rian de Laat; John Elsworth; Toby B Cole; Judit Marsillach; Clement E Furlong; Lucio G Costa
Journal:  Chem Biol Interact       Date:  2016-04-07       Impact factor: 5.192

Review 10.  Parkinson's disease treatment: past, present, and future.

Authors:  John D Elsworth
Journal:  J Neural Transm (Vienna)       Date:  2020-03-14       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.